QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maia-biotechnology-announces-independent-director-ms-adelina-louie-ngar-yee-made-an-individual-purchase-of-19665-shares-and-warrants-for-19665-shares-of-common-stock

Original seed investor has remained top MAIA stockholderMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company...

 maia-biotechnology-announces-170940--share-purchase-by-director-adelina-louie-in-private-placement

Five independent members of MAIA's Board of Directors purchased shares in the offeringMAIA Biotechnology, Inc., (NYSE:MAIA)...

 maia-biotechnology-announces-133m-private-placement-of-06m-shares-at-2295share

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company devel...

 maia-biotechnology-announces-170940-share-purchase-by-director-stan-smith-phd-in-a-29m-private-placement

Dr. Smith has participated in every MAIA funding roundMAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA," the "Company&#...

 maia-biotechnology-announces-efficacy-of-thio-combination-thio-180mg--cemiplimab-achieved-38-overall-response-rate-in-difficult-to-treat-third-line-non-small-cell-lung-cancer

Combination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, third-line non-small cell l...

 maia-biotechnology-ceo-details-immuno-oncology-cancer-treatment-candidates-and-development-pipeline-in-letter-to-shareholders

THIO-101 Phase 2 trial nears completion with survival and response data forthcoming; exploration of multiple cancer indications...

 maia-biotechnology-completes-enrollment-in-thio-101-phase-2-clinical-trial-for-non-small-cell-lung-cancer

Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent i...

 maia-biotechnology-published-findings-regarding-effects-of-thio-for-potential-treatment-of-small-cell-lung-cancer

THIO treatment leads to profound activation of innate and adaptive anti-tumor responsesTHIO depletes cancer initiating cells (C...

 maia-biotechnology-provides-phase-2-clinical-updates-for-lead-anticancer-agent-and-outlines-targeted-milestones-for-2024

Lead candidate THIO maintains unprecedented disease control rates in Phase 2 non-small cell lung cancer (NSCLC) clinical trialM...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION